Arild Nesbakken

• Langerud, Jonas; Eilertsen, Ina Andrassy; Moosavi, Hossein; Klokkerud, Solveig Margrete Knoph; Reims, Henrik Mikael & Backe, Ingeborg Flåten [Show all 13 contributors for this article] (2024). Multiregional transcriptomics identifies congruent consensus subtypes with prognostic value beyond tumor heterogeneity of colorectal cancer. Nature Communications. ISSN 2041-1723. 15(1). doi: 10.1038/s41467-024-48706-2.
• Majid, Umair; Bergsland, Christian Holst; Sveen, Anita; Bruun, Jarle; Eilertsen, Ina Andrassy & Bækkevold, Espen Sønderaal [Show all 10 contributors for this article] (2024). The prognostic effect of tumor-associated macrophages in stage I-III colorectal cancer depends on T cell infiltration. Cellular Oncology. ISSN 2211-3428. doi: 10.1007/s13402-024-00926-w.
• Rostoft, Siri ; Thomas, Michael; Jordhøy, Marit Slaaen; Møller, Bjørn; Nesbakken, Arild & Syse, Astri (2023). Hospital use and cancer treatment by age and socioeconomic status in the last year of life: A Norwegian population-based study of patients dying of cancer. Journal of Geriatric Oncology. ISSN 1879-4068. 15(2). doi: 10.1016/j.jgo.2023.101683. Full text in Research Archive
• Kleppe, Andreas; Skrede, Ole-Johan; De Raedt, Sepp; Hveem, Tarjei Sveinsgjerd; Askautrud, Hanne Arenberg & Jacobsen, Jørn E. [Show all 14 contributors for this article] (2022). A clinical decision support system optimising adjuvant chemotherapy for colorectal cancers by integrating deep learning and pathological staging markers: a development and validation study. The Lancet Oncology. ISSN 1470-2045. 23(9), p. 1221–1232. doi: 10.1016/S1470-2045(22)00391-6. Show summary

  The DoMore-v1-CRC marker was recently developed using deep learning and conventional haematoxylin and eosin-stained tissue sections, and was observed to outperform established molecular and morphological markers of patient outcome after primary colorectal cancer resection. The aim of the present study was to develop a clinical decision support system based on DoMore-v1-CRC and pathological staging markers to facilitate individualised selection of adjuvant treatment. Methods We estimated cancer-specific survival in subgroups formed by pathological tumour stage (pT<4 or pT4), pathological nodal stage (pN0, pN1, or pN2), number of lymph nodes sampled (≤12 or >12) if not pN2, and DoMore-v1-CRC classification (good, uncertain, or poor prognosis) in 997 patients with stage II or III colorectal cancer considered to have no residual tumour (R0) from two community-based cohorts in Norway and the UK, and used these data to define three risk groups. An external cohort of 1075 patients with stage II or III R0 colorectal cancer from the QUASAR 2 trial was used for validation; these patients were treated with single-agent capecitabine. The proposed risk stratification system was evaluated using Cox regression analysis. We similarly evaluated a risk stratification system intended to reflect current guidelines and clinical practice. The primary outcome was cancer-specific survival. Findings The new risk stratification system provided a hazard ratio of 10·71 (95% CI 6·39–17·93; p<0·0001) for high-risk versus low-risk patients and 3·06 (1·73–5·42; p=0·0001) for intermediate versus low risk in the primary analysis of the validation cohort. Estimated 3-year cancer-specific survival was 97·2% (95% CI 95·1–98·4; n=445 [41%]) for the low-risk group, 94·8% (91·7–96·7; n=339 [32%]) for the intermediate-risk group, and 77·6% (72·1–82·1; n=291 [27%]) for the high-risk group. The guideline-based risk grouping was observed to be less prognostic and informative (the low-risk group comprised only 142 [13%] of the 1075 patients). Interpretation Integrating DoMore-v1-CRC and pathological staging markers provided a clinical decision support system that risk stratifies more accurately than its constituent elements, and identifies substantially more patients with stage II and III colorectal cancer with similarly good prognosis as the low-risk group in current guidelines. Avoiding adjuvant chemotherapy in these patients might be safe, and could reduce morbidity, mortality, and treatment costs.

• Bergsland, Christian Holst; Jeanmougin, Marine; Moosavi, Seyed Hossein; Svindland, Aud; Bruun, Jarle & Nesbakken, Arild [Show all 8 contributors for this article] (2022). Spatial analysis and CD25-expression identify regulatory T cells as predictors of a poor prognosis in colorectal cancer. Modern Pathology. ISSN 0893-3952. 35, p. 1236–1246. doi: 10.1038/s41379-022-01086-8. Full text in Research Archive
• Sveen, Anita; Johannessen, Bjarne; Eilertsen, Ina Andrassy; Røsok, Bård Ingvald; Gulla, Marie & Eide, Peter Andreas Wold [Show all 14 contributors for this article] (2021). The expressed mutational landscape of microsatellite stable colorectal cancers. Genome Medicine. ISSN 1756-994X. 13. doi: 10.1186/s13073-021-00955-2. Full text in Research Archive
• Bruun, Jarle; Eide, Peter Andreas Wold; Bergsland, Christian Holst; Brück, Oscar; Svindland, Aud & Arjama, Mariliina [Show all 13 contributors for this article] (2021). E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models. Molecular Oncology. ISSN 1574-7891. 00, p. 1–18. doi: 10.1002/1878-0261.13159. Full text in Research Archive
• Moosavi, Seyed Hossein; Eide, Peter Andreas Wold; Eilertsen, Ina Andrassy; Brunsell, Tuva Høst; Berg, Kaja Christine Graue & Røsok, Bård Ingvald [Show all 12 contributors for this article] (2021). De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity. Genome Medicine. ISSN 1756-994X. 13, p. 143–143. doi: 10.1186/s13073-021-00956-1. Full text in Research Archive
• Slørdahl, Kathinka; Klotz, Dagmar; Olsen, Jan Åge; Skovlund, Eva; Undseth, Christine & Abildgaard, Heidi L. [Show all 17 contributors for this article] (2021). Treatment outcomes and prognostic factors after chemoradiotherapy for anal cancer. Acta Oncologica. ISSN 0284-186X. 60(7), p. 921–930. doi: 10.1080/0284186X.2021.1918763. Full text in Research Archive
• Eide, Peter Andreas Wold; Moosavi, Seyed Hossein; Eilertsen, Ina Andrassy; Brunsell, Tuva Høst; Langerud, Jonas & Berg, Kaja Christine Graue [Show all 11 contributors for this article] (2021). Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancer. NPJ GENOMIC MEDICINE. ISSN 2056-7944. 6:59, p. 1–9. doi: 10.1038/s41525-021-00223-7. Full text in Research Archive
• Kleive, Dyre; Aas, Eline; Angelsen, Jon-Helge; Bringeland, Erling Audun; Nesbakken, Arild & Nymo, Linn Såve [Show all 9 contributors for this article] (2021). Simultaneous Resection of Primary Colorectal Cancer and Synchronous Liver Metastases: Contemporary Practice, Evidence and Knowledge Gaps. Oncology and Therapy. ISSN 2366-1070. 9(1), p. 111–120. doi: 10.1007/s40487-021-00148-2. Full text in Research Archive
• Kryeziu, Kushtrim; Moosavi, Seyed Hossein; Bergsland, Christian Holst; Guren, Marianne; Eide, Peter Andreas Wold & Totland, Max [Show all 11 contributors for this article] (2021). Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases. Journal of Translational Medicine. ISSN 1479-5876. 19:384, p. 1–11. doi: 10.1186/s12967-021-03062-3. Full text in Research Archive
• Gallo, Gaetano; Pata, Francesco; Vennix, S.; Laurberg, S.; Morton, D. & Rubbini, M. [Show all 1,087 contributors for this article] (2020). Predictors for anastomotic leak, postoperative complications, and mortality after right colectomy for cancer: Results from an international snapshot audit. Diseases of the Colon & Rectum. ISSN 0012-3706. 63(5), p. 606–618. doi: 10.1097/DCR.0000000000001590.
• Bruun, Jarle; Kryeziu, Kushtrim; Eide, Peter Andreas Wold; Moosavi, Seyed Hossein; Eilertsen, Ina Andrassy & Røsok, Bård Ingvald [Show all 21 contributors for this article] (2020). Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity. Clinical Cancer Research. ISSN 1078-0432. 26(15), p. 4107–4119. doi: 10.1158/1078-0432.CCR-19-3637. Show summary

  Abstract Purpose: Molecular tumor heterogeneity may have important implications for the efficacy of targeted therapies in metastatic cancers. Inter-metastatic heterogeneity of sensitivity to anticancer agents has not been well explored in colorectal cancer. Experimental Design: We established a platform for ex vivo pharmacogenomic profiling of patient-derived organoids (PDO) from resected colorectal cancer liver metastases. Drug sensitivity testing (n = 40 clinically relevant agents) and gene expression profiling were performed on 39 metastases from 22 patients. Results: Three drug–response clusters were identified among the colorectal cancer metastases, based primarily on sensitivities to EGFR and/or MDM2 inhibition, and corresponding with RAS mutations and TP53 activity. Potentially effective therapies, including off-label use of drugs approved for other cancer types, could be nominated for eighteen patients (82%). Antimetabolites and targeted agents lacking a decisive genomic marker had stronger differential activity than most approved chemotherapies. We found limited intra-patient drug sensitivity heterogeneity between PDOs from multiple (2–5) liver metastases from each of ten patients. This was recapitulated at the gene expression level, with a highly proportional degree of transcriptomic and pharmacological variation. One PDO with a multi-drug resistance profile, including resistance to EGFR inhibition in a RAS-mutant background, showed sensitivity to MEK plus mTOR/AKT inhibition, corresponding with low-level PTEN expression. Conclusions: Intra-patient inter-metastatic pharmacological heterogeneity was not pronounced and ex vivo drug screening may identify novel treatment options for metastatic colorectal cancer. Variation in drug sensitivities was reflected at the transcriptomic level, suggesting potential to develop gene expression–based predictive signatures to guide experimental therapies.

• Smeby, Jørgen; Kryeziu, Kushtrim; Berg, Kaja Christine Graue; Eilertsen, Ina Andrassy; Eide, Peter Andreas Wold & Johannessen, Bjarne [Show all 11 contributors for this article] (2020). Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. EBioMedicine. ISSN 2352-3964. 59:102923, p. 1–13. doi: 10.1016/j.ebiom.2020.102923. Full text in Research Archive
• Berg, Kaja Christine Graue; Brunsell, Tuva Høst; Sveen, Anita; Alagaratnam, Sharmini; Bjørnslett, Merete Pauline & Hektoen, Merete [Show all 11 contributors for this article] (2020). Genomic and prognostic heterogeneity among RAS/BRAFV600E/TP53 co-mutated resectable colorectal liver metastases. Molecular Oncology. ISSN 1574-7891. p. 1–16. doi: 10.1002/1878-0261.12885. Full text in Research Archive
• Bergsland, Christian Holst; Bruun, Jarle; Guren, Marianne; Svindland, Aud; Bjørnslett, Merete Pauline & Smeby, Jørgen [Show all 16 contributors for this article] (2020). Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer. ESMO Open. ISSN 2059-7029. 5:e001040(6), p. 1–12. doi: 10.1136/esmoopen-2020-001040. Full text in Research Archive
• Skrede, Ole-Johan; De Raedt, Sepp; Kleppe, Andreas; Hveem, Tarjei Sveinsgjerd; Liestøl, Knut & Maddison, John [Show all 20 contributors for this article] (2020). Deep learning for prediction of colorectal cancer outcome: a discovery and validation study. The Lancet. ISSN 0140-6736. 395:10221, p. 350–360. doi: 10.1016/S0140-6736(19)32998-8. Full text in Research Archive
• Eilertsen, Ina Andrassy; Moosavi, Seyed Hossein; Strømme, Jonas Meier; Nesbakken, Arild; Johannessen, Bjarne & Lothe, Ragnhild A [Show all 7 contributors for this article] (2019). Technical differences between sequencing and microarray platforms impact transcriptomic subtyping of colorectal cancer. Cancer Letters. ISSN 0304-3835. 469, p. 246–255. doi: 10.1016/j.canlet.2019.10.040. Full text in Research Archive
• Brunsell, Tuva Høst; Sveen, Anita; Bjørnbeth, Bjørn Atle; Røsok, Bård Ingvald; Danielsen, Stine Aske & Brudvik, Kristoffer Watten [Show all 13 contributors for this article] (2019). High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases. Clinical colorectal cancer. ISSN 1533-0028. 19(1), p. 26–47. doi: 10.1016/j.clcc.2019.09.003. Full text in Research Archive
• da Costa Florim Ribeiro Lopes, Nair Susana; Bergsland, Christian Holst; Bjørnslett, Merete Pauline; Pellinen, Teijo Severi; Svindland, Aud & Nesbakken, Arild [Show all 10 contributors for this article] (2019). Digital image analysis of multiplex fluorescence IHC in colorectal cancer recognizes the prognostic value of CDX2 and its negative correlation with SOX2. Laboratory Investigation. ISSN 0023-6837. 100(1), p. 120–134. doi: 10.1038/s41374-019-0336-4. Full text in Research Archive
• Dienstmann, Rodrigo; Villacampa, Guillermo; Sveen, Anita; Mason, Michael J.; Niedzwiecki, Donna & Nesbakken, Arild [Show all 10 contributors for this article] (2019). Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer. Annals of Oncology. ISSN 0923-7534. 30(10), p. 1622–1629. doi: 10.1093/annonc/mdz287. Full text in Research Archive
• Glaire, Mark A; Domingo, Enric; Sveen, Anita; Bruun, Jarle; Nesbakken, Arild & Nicholson, George [Show all 16 contributors for this article] (2019). Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage. British Journal of Cancer. ISSN 0007-0920. 121, p. 474–482. doi: 10.1038/s41416-019-0540-4. Full text in Research Archive
• Joranger, Pål; Nesbakken, Arild; Sorbye, Halfdan; Hoff, Geir; Oshaug, Arne & Aas, Eline (2019). Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach. European Journal of Health Economics. ISSN 1618-7598. p. 1–14. doi: 10.1007/s10198-019-01130-6. Full text in Research Archive Show summary

  New and emerging advances in colorectal cancer (CRC) treatment combined with limited healthcare resources highlight the need for detailed decision-analytic models to evaluate costs, survival and quality-adjusted life years. The objectives of this article were to estimate the expected lifetime treatment cost of CRC for an average 70-year-old patient and to test the applicability and flexibility of a model in predicting survival and costs of changing treatment scenarios. The analyses were based on a validated semi-Markov model using data from a Norwegian observational study (2049 CRC patients) to estimate transition probabilities and the proportion resected. In addition, inputs from the Norwegian Patient Registry, guidelines, literature, and expert opinions were used to estimate resource use. We found that the expected lifetime treatment cost for a 70-year-old CRC patient was €47,300 (CRC stage I €26,630, II €38,130, III €56,800, and IV €69,890). Altered use of palliative chemotherapy would increase the costs by up to 29%. A 5% point reduction in recurrence rate for stages I-III would reduce the costs by 5.3% and increase overall survival by 8.2 months. Given the Norwegian willingness to pay threshold per QALY gained, society's willingness to pay for interventions that could result in such a reduction was on average €28,540 per CRC patient. The life years gained by CRC treatment were 6.05 years. The overall CRC treatment costs appear to be low compared to the health gain, and the use of palliative chemotherapy can have a major impact on cost. The model was found to be flexible and applicable for estimating the cost and survival of several CRC treatment scenarios.

• Smeby, Jørgen; Sveen, Anita; Bergsland, Christian Holst; Eilertsen, Ina Andrassy; Danielsen, Stine Aske & Eide, Peter Andreas Wold [Show all 11 contributors for this article] (2019). Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer. ESMO Open. ISSN 2059-7029. 4:e000523(3), p. 1–10. doi: 10.1136/esmoopen-2019-000523. Full text in Research Archive
• Brunsell, Tuva Høst; Cengija, Vanja; Sveen, Anita; Bjørnbeth, Bjørn Atle; Røsok, Bård Ingvald & Brudvik, Kristoffer Watten [Show all 10 contributors for this article] (2019). Heterogeneous radiological response to neoadjuvant therapy is associated with poor prognosis after resection of colorectal liver metastases. European Journal of Surgical Oncology. ISSN 0748-7983. p. 1–7. doi: 10.1016/j.ejso.2019.07.017. Full text in Research Archive
• Berg, Kaja Christine Graue; Sveen, Anita; Høland, Maren; Alagaratnam, Sharmini; Rasmussen, Marianne Berg & Danielsen, Stine Aske [Show all 9 contributors for this article] (2019). Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains. Oncogene. ISSN 0950-9232. 38(33), p. 6109–6122. doi: 10.1038/s41388-019-0868-5. Full text in Research Archive
• Smeby, Jørgen; Sveen, Anita; Eilertsen, Ina Andrassy; Danielsen, Stine Aske; Hoff, Andreas Midbøe & Eide, Peter Andreas Wold [Show all 12 contributors for this article] (2019). Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer. Oncogenesis. ISSN 2157-9024. 8:35(6), p. 1–8. doi: 10.1038/s41389-019-0141-3. Full text in Research Archive
• Eilertsen, Ina Andrassy; Sveen, Anita; Strømme, Jonas Meier; Skotheim, Rolf I.; Nesbakken, Arild & Lothe, Ragnhild A (2018). Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancer . International Journal of Cancer. ISSN 0020-7136. 144(4), p. 841–847. doi: 10.1002/ijc.31809. Full text in Research Archive Show summary

  KRAS mutation is a well‐known marker for poor response to targeted treatment and patient prognosis in microsatellite stable (MSS) colorectal cancer (CRC). However, variation in clinical outcomes among patients wild‐type for KRAS underlines that this is not a homogeneous population. Here, we evaluated the prognostic impact of KRAS alternative splicing in relation to mutation status in a single‐hospital series of primary MSS CRCs (N = 258). Using splicing‐sensitive microarrays and RNA sequencing, the relative expression of KRAS‐4A versus KRAS‐4B transcript variants was confirmed to be down‐regulated in CRC compared to normal colonic mucosa (N = 41; p ≤ 0.001). This was independent of mutation status, however, gene set enrichment analysis revealed that the effect of splicing on KRAS signaling was specific to the KRAS wild‐type subgroup, in which low relative KRAS‐4A expression was associated with a higher level of KRAS signaling (p = 0.005). In concordance, the prognostic value of KRAS splicing was also dependent on mutation status, and for patients with Stage I–III KRAS wild‐type MSS CRC, low relative KRAS‐4A expression was associated with inferior overall survival (HR: 2.36, 95% CI: 1.07–5.18, p = 0.033), a result not found in mutant cases (pinteraction = 0.026). The prognostic association in the wild‐type subgroup was independent of clinicopathological factors, including cancer stage in multivariable analysis (HR: 2.68, 95% CI: 1.18–6.09, p = 0.018). This suggests that KRAS has prognostic value beyond mutation status in MSS CRC, and highlights the importance of molecular heterogeneity in the clinically relevant KRAS wild‐type subgroup.

• Gleditsch, Dagfinn; Wexels, Wilhelm Andreas & Nesbakken, Arild (2018). Surgical options and trends in treating rectal prolapse: long-term results in a 19-year follow-up study. Langenbeck's Archives of Surgery. ISSN 1435-2443. p. 1–8. doi: 10.1007/s00423-018-1728-4. Full text in Research Archive
• Bruun, Jarle; Sveen, Anita; Barros, Rita; Eide, Peter Andreas Wold; Eilertsen, Ina Andrassy & Kolberg, Matthias [Show all 14 contributors for this article] (2018). Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer. Molecular Oncology. ISSN 1574-7891. 12(9), p. 1639–1655. doi: 10.1002/1878-0261.12347. Full text in Research Archive
• Ommundsen, Nina; Nesbakken, Arild; Wyller, Torgeir Bruun; Skovlund, Eva; Bakka, Arne Olav & Jordhøy, Marit Slaaen [Show all 7 contributors for this article] (2018). Post-discharge complications in frail older patients after surgery for colorectal cancer. European Journal of Surgical Oncology. ISSN 0748-7983. 44(10), p. 1542–1547. doi: 10.1016/j.ejso.2018.06.024. Full text in Research Archive
• Smeby, Jørgen; Sveen, Anita; Merok, Marianne Aarstad; Danielsen, Stine Aske; Eilertsen, Ina Andrassy & Guren, Marianne [Show all 9 contributors for this article] (2018). CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. Annals of Oncology. ISSN 0923-7534. 29(5), p. 1227–1234. doi: 10.1093/annonc/mdy085. Full text in Research Archive
• Vedeld, Hege Marie; Nesbakken, Arild; Lothe, Ragnhild A & Lind, Guro Elisabeth (2018). Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer. Clinical Epigenetics. ISSN 1868-7075. 10(1). doi: 10.1186/s13148-018-0503-2.
• Kleppe, Andreas; Albregtsen, Fritz; Vlatkovic, Ljiljana; Pradhan, Manohar; Nielsen, Birgitte & Hveem, Tarjei Sveinsgjerd [Show all 16 contributors for this article] (2018). Chromatin organisation and cancer prognosis: a pan-cancer study. The Lancet Oncology. ISSN 1470-2045. 19(3), p. 356–369. doi: 10.1016/S1470-2045(17)30899-9. Full text in Research Archive
• El-Hussuna, Alaa; Pinkney, Thomas; Zmora, Oded; Frasson, Murili Zomer; Bhangu, Aneel & Battersby, Nicholas J. [Show all 24 contributors for this article] (2018). Risk factors for unfavourable postoperative outcome in patients with Crohn’s disease undergoing right hemicolectomy or ileocaecal resection. An international audit by ESCP and S-ECCO . Colorectal Disease. ISSN 1462-8910. 20(3), p. 219–227. doi: 10.1111/codi.13889.
• Ommundsen, Nina; Wyller, Torgeir Bruun; Nesbakken, Arild; Bakka, Arne Olav; Jordhøy, Marit Slaaen & Skovlund, Eva [Show all 7 contributors for this article] (2018). Preoperative geriatric assessment and tailored interventions in frail older patients with colorectal cancer: a randomized controlled trial. Colorectal Disease. ISSN 1462-8910. 20(1), p. 16–25. doi: 10.1111/codi.13785.
• Danielsen, Håvard Emil; Hveem, Tarjei Sveinsgjerd; Domingo, Enric; Pradhan, Manohar; Kleppe, Andreas & Syvertsen, Rolf Anders [Show all 18 contributors for this article] (2018). Prognostic markers for colorectal cancer: Estimating ploidy and stroma. Annals of Oncology. ISSN 0923-7534. 29(3), p. 616–623. doi: 10.1093/annonc/mdx794.
• Sveen, Anita; Bruun, Jarle; Eide, Peter Andreas Wold; Eilertsen, Ina Andrassy; Ramirez, Lorena & Murumagi, Astrid [Show all 17 contributors for this article] (2017). Colorectal cancer consensus molecular subtypes translated to preclinical models uncover potentially targetable cancer cell dependencies. Clinical Cancer Research. ISSN 1078-0432. 24(4), p. 794–806. doi: 10.1158/1078-0432.CCR-17-1234.
• Dienstmann, Rodrigo; Mason, M; Sinicrope, FA; Phipps, Alison; Tejpar, S. & Nesbakken, Arild [Show all 14 contributors for this article] (2017). Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Annals of Oncology. ISSN 0923-7534. 28(5), p. 1023–1031. doi: 10.1093/annonc/mdx052. Full text in Research Archive
• Labori, Knut Jørgen; Guren, Marianne; Brudvik, Kristoffer Watten; Røsok, Bård Ingvald; Waage, Anne & Nesbakken, Arild [Show all 10 contributors for this article] (2017). Resection of synchronous liver metastases between radiotherapy and definitive surgery for locally advanced rectal cancer: short-term surgical outcomes, overall survival and recurrence-free survival. Colorectal Disease. ISSN 1462-8910. 19(8), p. 731–738. doi: 10.1111/codi.13622.
• Vedeld, Hege Marie; Merok, Marianne Aarstad; Jeanmougin, Marine; Danielsen, Stine Aske; Honne, Hilde & Presthus, Gro [Show all 13 contributors for this article] (2017). CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers. International Journal of Cancer. ISSN 0020-7136. 141(5), p. 967–976. doi: 10.1002/ijc.30796.
• Sveen, Anita; Bruun, Jarle; Eide, Peter W.; Eilertsen, Ina A.; Ramirez, Lorena & Murumagi, Astrid [Show all 17 contributors for this article] (2017). Colorectal cancer consensus molecular subtypes define selective activity of HSP90 inhibitors in preclinical models. Cancer Reports and Reviews. ISSN 2513-9290. doi: 10.1158/1078-0432.CCR-17-1234.
• Sveen, Anita; Johannessen, Bjarne; Tengs, Torstein; Danielsen, Stine Aske; Eilertsen, Ina Andrassy & Lind, Guro Elisabeth [Show all 16 contributors for this article] (2017). Multilevel genomics of colorectal cancers with microsatellite instability – clinical impact of JAK1 mutations and consensus molecular subtype 1. Genome Medicine. ISSN 1756-994X. 9(1). doi: 10.1186/s13073-017-0434-0.
• Domingo, Enric; Freeman-Mills, Luke; Rayner, Emily; Glaire, Mark; Briggs, Sarah & Vermeulen, Louis [Show all 35 contributors for this article] (2016). Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. The Lancet Gastroenterology and Hepatology. ISSN 2468-1253. 1(3), p. 207–216. doi: 10.1016/S2468-1253(16)30014-0.
• Pedersen, Kjetil Boye; Jacob, Havjin; Frikstad, Kari-Anne; Nesland, Jahn M; Mælandsmo, Gunhild & Dahl, Olav [Show all 8 contributors for this article] (2016). Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy. Cancer Medicine. ISSN 2045-7634. 5(8), p. 1840–1849. doi: 10.1002/cam4.766. Full text in Research Archive
• Gleditsch, Dagfinn; Søreide, Ole Kristian & Nesbakken, Arild (2016). Managing Malignant Colorectal Obstruction with Self-Expanding Stents. A Closer Look at Bowel Perforations and Failed Procedures. Journal of Gastrointestinal Surgery. ISSN 1091-255X. p. 1–7. doi: 10.1007/s11605-016-3186-z.
• Stornes, Tore; Wibe, Arne; Nesbakken, Arild; Myklebust, Tor Åge & Endreseth, Birger Henning (2016). National early rectal cancer treatment revisited. Diseases of the Colon & Rectum. ISSN 0012-3706. 59(7), p. 623–629. doi: 10.1097/DCR.0000000000000591.
• Rønning, Benedicte; Wyller, Torgeir Bruun; Nesbakken, Arild; Skovlund, Eva; Jordhøy, Marit Slaaen & Bakka, Arne Olav [Show all 7 contributors for this article] (2016). Quality of life in older and frail patients after surgery for colorectal cancer-A follow-up study. Journal of Geriatric Oncology. ISSN 1879-4068. 7(3), p. 195–200. doi: 10.1016/j.jgo.2016.03.002. Show summary

  Objective The incidence of colorectal cancer is increasing, mainly due to the aging of the population. Frailty, describing a state of increased vulnerability, is common in older patients, but frailty and high age are not necessarily contraindications to surgical treatment. However, limited data describing long-term outcomes after surgery in this patient group exist. In this clinical follow-up study, we aimed to examine long-term health-related quality of life in older surgical patients with colorectal cancer. Materials and Methods Patients were recruited from a prospective multicenter study investigating frailty as a predictor of postoperative complications after surgery for colorectal cancer. A preoperative geriatric assessment was performed, and patients were classified as frail or non-frail. Patients responded to version 3.0 of The European Organisation of Research and Treatment of Cancer Quality of Life Questionnaire-C30 before surgery, 3 months postoperatively and at a long-term follow-up 16–28 months (median 22 months) after surgery. One-way repeated-measures analyses of variance were performed to examine changes in scores over time. Results 180 patients with a mean age of 80 years were included at baseline, 138 at 3 months postoperatively, and 84 patients (69% of survivors) at long-term follow-up. A significant improvement in quality of life-scores was present 3 months after surgery, also in the subgroup of frail patients. At long-term follow-up, scores decreased, but to values above baseline. Conclusion Health-related quality of life may be improved in older patients after surgery for colorectal cancer, even in patients who are classified as frail preoperatively.

• Guren, Marianne; Kørner, Hartwig; Pfeffer, Frank; Myklebust, Tor Åge; Eriksen, Morten Tandberg & Edna, Tom-Harald [Show all 23 contributors for this article] (2015). Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993-2010. Acta Oncologica. ISSN 0284-186X. 54(10), p. 1714–1722. doi: 10.3109/0284186X.2015.1034876.
• Bruun, Jarle; Kolberg, Matthias; Ahlquist, Terje Cruickshank; Røyrvik, Ellen Christine; Nome, Torfinn & Leithe, Edward [Show all 18 contributors for this article] (2015). Regulator of chromosome condensation 2 identifies high-risk patients within both major phenotypes of colorectal cancer. Clinical Cancer Research. ISSN 1078-0432. 21(16), p. 3759–3770. doi: 10.1158/1078-0432.CCR-14-3294.
• Danielsen, Stine Aske; Eide, Peter Andreas Wold; Nesbakken, Arild; Guren, Tormod Kyrre; Leithe, Edward & Lothe, Ragnhild A (2015). Portrait of the PI3K/AKT pathway in colorectal cancer. Acta Biochimica et Biophysica Sinica. ISSN 0582-9879. 1855(1), p. 104–121. doi: 10.1016/j.bbcan.2014.09.008.
• Joranger, Pål; Nesbakken, Arild; Hoff, Geir; Sorbye, Halfdan; Oshaug, Arne & Aas, Eline (2015). Modeling and Validating the Cost and Clinical Pathway of Colorectal Cancer. Medical decision making. ISSN 0272-989X. 35(2), p. 255–265. doi: 10.1177/0272989X14544749. Full text in Research Archive
• Hveem, Tarjei Sveinsgjerd; Merok, Marianne Aarstad; Pretorius, Maria; Novelli, Marco; Silihagen, Mette & Sjo, Ole Helmer [Show all 12 contributors for this article] (2014). Prognostic impact of genomic instability in colorectal cancer. British Journal of Cancer. ISSN 0007-0920. 110(8), p. 2159–2164. doi: 10.1038/bjc.2014.133.
• Ommundsen, Nina; Wyller, Torgeir Bruun; Nesbakken, Arild; Jordhøy, Marit; Bakka, Arne Olav & Skovlund, Eva [Show all 7 contributors for this article] (2014). Frailty is an independent predictor of survival in older patients with colorectal cancer. The Oncologist. ISSN 1083-7159. 19(12), p. 1268–1275. doi: 10.1634/theoncologist.2014-0237. Show summary

  Background. Colorectal cancer (CRC) is prevalent in the older population. Geriatric assessment (GA) has previously been found to predict treatment tolerance and postoperative complications in older cancer patients. The aim of this study was to explore whether GA also predicts 1-year and 5-year survival after CRC surgery in older patients and to compare the predictive power of GA with that of established prognostic factors such as TNM classification of malignant tumors (TNM) stage and age. Materials and Methods. A cohort of 178 CRC patients aged 70 and older were followed prospectively. All patients went through elective surgery, and GA was performed presurgery. The GA resulted in patients being divided into two groups: frail or nonfrail. All patients were followed for 5 years or until death. Data were analyzed by Kaplan-Meier plots and the Cox proportional hazards model. Results. Seventy-six patients (43%) were frail, and one hundred and two (57%) were nonfrail. Twenty-three patients (13%) died during the first year after surgery. One-year survival was 80% in the frail group and 92% in the nonfrail group. Five-year survival was significantly lower in frail (24%) than nonfrail patients (66%), and this difference was apparent both within the stratums of TNM stages 0–II and TNM stage III. In multivariable analysis adjusting for TNM stage, age, and sex, frailty was an independent prognostic factor for survival. Conclusion. A GA-based frailty assessment predicts 1-year and 5-year survival in older patients after surgery for CRC. In localized and regional disease, the impact of frailty upon 5-year survival is comparable with that of TNM stage.

• Vedeld, Hege Marie; Andresen, Kim; Eilertsen, Ina Andrassy; Nesbakken, Arild; Seruca, Raquel & Gladhaug, Ivar Prydz [Show all 10 contributors for this article] (2014). The novel colorectal cancer biomarkers CDO1, ZSCAN18 and ZNF331 are frequently methylated across gastrointestinal cancers. International Journal of Cancer. ISSN 0020-7136. 136(4), p. 844–853. doi: 10.1002/ijc.29039.
• Løvf, Marthe; Nome, Torfinn; Bruun, Jarle; Eknæs, Mette; Bakken, Anne Cathrine & Mpindi, John-Patrick [Show all 12 contributors for this article] (2014). A novel transcript, VNN1-AB, as a biomarker for colorectal cancer. International Journal of Cancer. ISSN 0020-7136. 135(9), p. 2077–2084. doi: 10.1002/ijc.28855.
• Bruun, Jarle; Kolberg, Matthias; Nesland, Jahn M; Svindland, Aud; Nesbakken, Arild & Lothe, Ragnhild A (2014). Prognostic significance of β-catenin, E-cadherin, and SOX9 in colorectal cancer: Results from a large population-representative series. Frontiers in Oncology. ISSN 2234-943X. 4 MAY. doi: 10.3389/fonc.2014.00118.
• Ingebrigtsen, Vibeke Anett; Boye, Kjetil; Nesland, Jahn M; Nesbakken, Arild; Flatmark, Kjersti & Fodstad, Øystein (2014). B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome. BMC Cancer. ISSN 1471-2407. 20(14). doi: 10.1186/1471-2407-14-602.
• Søndenaa, Karl; Quirke, Philip; Hohenberger, Werner; Sugihara, Kenichi; Kobayashi, Hirotoshi & Kessler, Hermann [Show all 16 contributors for this article] (2014). The rationale behind complete mesocolic excision (CME) and a central vascular ligation for colon cancer in open and laparoscopic surgery: Proceedings of a consensus conference. International Journal of Colorectal Disease. ISSN 0179-1958. 29(4), p. 419–428. doi: 10.1007/s00384-013-1818-2.
• Nome, Torfinn; Hoff, Andreas Midbøe; Bakken, Anne Cathrine; Rognum, Torleiv Ole; Nesbakken, Arild & Skotheim, Rolf Inge (2014). High frequency of fusion transcripts involving TCF7L2 in colorectal cancer: Novel fusion partner and splice variants. PLOS ONE. ISSN 1932-6203. 9(3). doi: 10.1371/journal.pone.0091264. Full text in Research Archive
• Rønning, Benedicte; Wyller, Torgeir Bruun; Jordhøy, Marit Slaaen; Nesbakken, Arild; Bakka, Arne Olav & Seljeflot, Ingebjørg [Show all 7 contributors for this article] (2014). Frailty indicators and functional status in older patients after colorectal cancer surgery. Journal of Geriatric Oncology. ISSN 1879-4068. 5(1), p. 26–32. doi: 10.1016/j.jgo.2013.08.001.
• Sveen, Anita; Nesbakken, Arild; Ågesen, Trude Holmeide; Guren, Marianne; Tveit, Magne Kjell & Skotheim, Rolf Inge [Show all 7 contributors for this article] (2013). Anticipating the Clinical Use of Prognostic Gene Expression-Based Tests for Colon Cancer Stage II and III: Is Godot Finally Arriving? Clinical Cancer Research. ISSN 1078-0432. 19(24), p. 6669–6677. doi: 10.1158/1078-0432.CCR-13-1769.
• Nome, Torfinn; Thomassen, Gard O Sundby; Bruun, Jarle; Ahlquist, Terje Cruickshank; Bakken, Anne Cathrine & Hoff, Andreas Midbøe [Show all 17 contributors for this article] (2013). Common fusion transcripts identified in colorectal cancer cell lines by high throughput RNA sequencing. Translational Oncology. ISSN 1944-7124. 6(5), p. 546–553. doi: 10.1593/tlo.13457. Full text in Research Archive
• Nedrebø, Bjørn Steinar Olden; Søreide, Kjetil; Nesbakken, Arild; Eriksen, Morten Tandberg; Søreide, Jon Arne & Kørner, Hartwig (2013). Risk factors associated with poor lymph node harvest after colon cancer surgery in a national cohort. Colorectal Disease. ISSN 1462-8910. 15(6), p. E301–E308. doi: 10.1111/codi.12245.
• Merok, Marianne Aarstad; Ahlquist, Terje Cruickshank; Røyrvik, Ellen Christine; Tufteland, Kjersti Forberg; Hektoen, Merete & Sjo, Ole Helmer [Show all 10 contributors for this article] (2013). Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series. Annals of Oncology. ISSN 0923-7534. 24(5), p. 1274–1282. doi: 10.1093/annonc/mds614.
• Ahmed, Deeqa ; Danielsen, Stine Aske; Ågesen, Trude Holmeide; Bretthauer, Michael; Thiis-Evensen, Espen & Hoff, Geir [Show all 10 contributors for this article] (2012). A tissue-based comparative effectiveness analysis of biomarkers for early detection of colorectal tumors. Clinical and Translational Gastroenterology. ISSN 2155-384X. 3. doi: 10.1038/ctg.2012.21.
• Sveen, Anita; Ågesen, Trude Holmeide; Nesbakken, Arild; Meling, Gunn Iren; Rognum, Torleiv Ole & Liestøl, Knut [Show all 8 contributors for this article] (2012). ColoGuidePro: A Prognostic 7-Gene Expression Signature for Stage III Colorectal Cancer Patients. Clinical Cancer Research. ISSN 1078-0432. 18(21), p. 6001–6010. doi: 10.1158/1078-0432.CCR-11-3302.
• Ågesen, Trude Holmeide; Sveen, Anita; Merok, Marianne Aarstad; Lind, Guro Elisabeth; Nesbakken, Arild & Skotheim, Rolf Inge [Show all 7 contributors for this article] (2012). ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. Gut. ISSN 0017-5749. 61(11), p. 1560–1567. doi: 10.1136/gutjnl-2011-301179.
• Sirnes, Solveig; Bruun, Jarle; Kolberg, Matthias; Kjenseth, Ane Hansen; Lind, Guro Elisabeth & Svindland, Aud [Show all 11 contributors for this article] (2012). Connexin43 acts as a colorectal cancer tumor suppressor and predicts disease outcome. International Journal of Cancer. ISSN 0020-7136. 131(3), p. 570–581. doi: 10.1002/ijc.26392.
• Larssen, Lene; Medhus, Asle Wilhelm; Kørner, Hartwig; Glomsaker, Tom Birger; Søberg, Taran & Gleditsch, Dagfinn [Show all 11 contributors for this article] (2012). Long-term outcome of palliative treatment with self-expanding metal stents for malignant obstructions of the GI tract. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 47(12), p. 1505–1514. doi: 10.3109/00365521.2012.711854.
• Sjo, Ole Helmer; Merok, Marianne Aarstad; Svindland, Aud & Nesbakken, Arild (2012). Prognostic Impact of Lymph Node Harvest and Lymph Node Ratio in Patients With Colon Cancer. Diseases of the Colon & Rectum. ISSN 0012-3706. 55(3), p. 307–315. doi: 10.1097/DCR.0b013e3182423f62.
• Kristjansson, Siri Rostoft; Rønning, Benedicte; Hurria, Arti; Skovlund, Eva; Jordhøy, Marit Slaaen & Nesbakken, Arild [Show all 7 contributors for this article] (2012). A comparison of two pre-operative frailty measures in older surgical cancer patients. Journal of Geriatric Oncology. ISSN 1879-4068. 3(1), p. 1–7. doi: 10.1016/j.jgo.2011.09.002.
• Sveen, Anita; Bakken, Anne Cathrine; Ågesen, Trude Holmeide; Lind, Guro Elisabeth; Nesbakken, Arild & Nordgård, Oddmund [Show all 10 contributors for this article] (2012). The exon-level biomarker SLC39A14 has organ-confined cancer-specificity in colorectal cancer. International Journal of Cancer. ISSN 0020-7136. 131(6), p. 1479–1485. doi: 10.1002/ijc.27399.
• Cekaite, Lina; Rantala, Juha K.; Bruun, Jarle; Guriby, Marianne; Ågesen, Trude Holmeide & Danielsen, Stine Aske [Show all 11 contributors for this article] (2012). MiR-9,-31, and-182 Deregulation Promote Proliferation and Tumor Cell Survival in Colon Cancer. Neoplasia. ISSN 1522-8002. 14(9), p. 868–U126. doi: 10.1593/neo.121094.
• Sveen, Anita; Ågesen, Trude Holmeide; Nesbakken, Arild; Rognum, Torleiv Ole; Lothe, Ragnhild A & Skotheim, Rolf Inge (2011). Transcriptome instability in colorectal cancer identified by exon microarray analyses: Associations with splicing factor expression levels and patient survival. Genome Medicine. ISSN 1756-994X. 3(5). doi: 10.1186/gm248.
• Sjo, Ole Helmer; Berg, Marianne; Merok, Marianne Aarstad; Kolberg, Matthias; Svindland, Aud & Lothe, Ragnhild A [Show all 7 contributors for this article] (2011). Peritoneal Carcinomatosis of Colon Cancer Origin: Highest Incidence in Women and in Patients With Right-Sided Tumors. Journal of Surgical Oncology. ISSN 0022-4790. 104(7), p. 792–797. doi: 10.1002/jso.21959.
• Ågesen, Trude Holmeide; Berg, Marianne; Clancy, Trevor; Thiis-Evensen, Espen; Cekaite, Lina & Lind, Guro Elisabeth [Show all 16 contributors for this article] (2011). CLC and IFNAR1 are differentially expressed and a global immunity score is distinct between early- and late-onset colorectal cancer. Genes and Immunity. ISSN 1466-4879. 12(8), p. 653–662. doi: 10.1038/gene.2011.43.
• Larssen, Lene; Medhus, Asle Wilhelm; Hjermstad, Marianne Jensen; Kørner, Hartwig; Glomsaker, Tom & Søberg, Taran [Show all 12 contributors for this article] (2011). Patient-reported outcomes in palliative gastrointestinal stenting: a Norwegian multicenter study. Surgical Endoscopy. ISSN 0930-2794. 25(10), p. 3162–3169. doi: 10.1007/s00464-011-1680-7.
• Danielsen, Stine Aske; Cekaite, Lina; Ågesen, Trude Holmeide; Sveen, Anita; Nesbakken, Arild & Thiis-Evensen, Espen [Show all 9 contributors for this article] (2011). Phospholipase C Isozymes Are Deregulated in Colorectal Cancer - Insights Gained from Gene Set Enrichment Analysis of the Transcriptome. PLOS ONE. ISSN 1932-6203. 6(9). doi: 10.1371/journal.pone.0024419.
• Lind, Guro Elisabeth; Danielsen, Stine Aske; Ahlquist, Terje Cruickshank; Merok, Marianne Aarstad; Andresen, Kim & Skotheim, Rolf Inge [Show all 14 contributors for this article] (2011). Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Molecular Cancer. ISSN 1476-4598. 10. doi: 10.1186/1476-4598-10-85.
• Lind, Guro Elisabeth; Raiborg, Camilla; Danielsen, Stine Aske; Rognum, Torleiv Ole; Thiis-Evensen, Espen & Hoff, Geir [Show all 9 contributors for this article] (2011). SPG20, a novel biomarker for early detection of colorectal cancer, encodes a regulator of cytokinesis. Oncogene. ISSN 0950-9232. 30(37), p. 3967–3978. doi: 10.1038/onc.2011.109.
• Hølmebakk, Søren Torben; Solbakken, Arne Mide; Mala, Tom & Nesbakken, Arild (2011). Clinical prediction of survival by surgeons for patients with incurable abdominal malignancy. European Journal of Surgical Oncology. ISSN 0748-7983. 37(7), p. 571–575. doi: 10.1016/j.ejso.2011.02.009.
• Nesbakken, Arild; Kristinsson, Jon Adalsteinn; Svindland, Aud & Lunde, Ole Christian (2011). ENDOSCOPIC SNARE RESECTION FOLLOWED BY LASER ABLATION IN THE TREATMENT OF LARGE, SESSILE RECTAL ADENOMAS. Scandinavian Journal of Surgery. ISSN 1457-4969. 100(2), p. 99–104.
• Færden, Arne Engebret; Sjo, Ole Helmer; Bukholm, Ida Rashida Khan; Andersen, Solveig Norheim; Svindland, Aud & Nesbakken, Arild [Show all 7 contributors for this article] (2011). Lymph Node Micrometastases and Isolated Tumor Cells Influence Survival in Stage I and II Colon Cancer. Diseases of the Colon & Rectum. ISSN 0012-3706. 54(2), p. 200–206. doi: 10.1007/DCR.0b013e3181fd4c7c.
• Andersson, Thea; Lunde, Ole Christian; Johnson, Egil; Moum, Torbjørn & Nesbakken, Arild (2011). Long-term functional outcome and quality of life after restorative proctocolectomy with ileo-anal anastomosis for colitis. Colorectal Disease. ISSN 1462-8910. 13(4), p. 431–437. doi: 10.1111/j.1463-1318.2009.02163.x.
• Kristjansson, Siri Rostoft; Jordhøy, Marit S; Nesbakken, Arild; Skovlund, Eva; Bakka, Arne Olav & Johannessen, Hans Olaf [Show all 7 contributors for this article] (2010). Which elements of a comprehensive geriatric assessment (CGA) predict post-operative complications and early mortality after colorectal cancer surgery? Journal of Geriatric Oncology. ISSN 1879-4068. 1(2), p. 57–65. doi: 10.1016/j.jgo.2010.06.001.
• Kristjansson, Siri Rostoft; Nesbakken, Arild; Jordhøy, Marit S; Skovlund, Eva; Audisio, Riccardo A. & Johannessen, Hans Olaf [Show all 8 contributors for this article] (2010). Comprehensive geriatric assessment can predict complications in elderly patients after elective surgery for colorectal cancer: A prospective observational cohort study. Critical Reviews in Oncology/Hematology. ISSN 1040-8428. 76(3), p. 208–217. doi: 10.1016/j.critrevonc.2009.11.002.
• Berg, Marianne; Danielsen, Stine Aske; Ahlquist, Terje Cruickshank; Merok, Marianne Aarstad; Ågesen, Trude Holmeide & Vatn, Morten H [Show all 17 contributors for this article] (2010). DNA Sequence Profiles of the Colorectal Cancer Critical Gene Set KRAS-BRAF-PIK3CA-PTEN-TP53 Related to Age at Disease Onset. PLOS ONE. ISSN 1932-6203. 5(11). doi: 10.1371/journal.pone.0013978.
• Knævelsrud, Helene; Ahlquist, Terje Cruickshank; Merok, Marianne Aarstad; Nesbakken, Arild; Stenmark, Harald Alfred & Lothe, Ragnhild A [Show all 7 contributors for this article] (2010). UVRAG mutations associated with microsatellite unstable colon cancer do not affect autophagy. Autophagy. ISSN 1554-8627. 6(7), p. 863–870. doi: 10.4161/auto.6.7.13033.
• Berg, Marianne; Ågesen, Trude Holmeide; Thiis-Evensen, Espen; Merok, Marianne Aarstad; Teixeira, Manuel & Vatn, Morten H [Show all 9 contributors for this article] (2010). Distinct high resolution genome profiles of early onset and late onset colorectal cancer integrated with gene expression data identify candidate susceptibility loci. Molecular Cancer. ISSN 1476-4598. 9. doi: 10.1186/1476-4598-9-100.
• Rønning, Benedicte; Wyller, Torgeir Bruun; Seljeflot, Ingebjørg; Jordhøy, Marit S; Skovlund, Eva & Nesbakken, Arild [Show all 7 contributors for this article] (2010). Frailty measures, inflammatory biomarkers and post-operative complications in older surgical patients. Age and Ageing. ISSN 0002-0729. 39(6), p. 758–761. doi: 10.1093/ageing/afq123.

View all works in Cristin

• Glaire, Mark; Domingo, Enric; Sveen, Anita; Bruun, Jarle; Nesbakken, Arild & Nicholson, George [Show all 16 contributors for this article] (2019). Correction: Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage (British Journal of Cancer, (2019), 121, 6, (474-482), 10.1038/s41416-019-0540-4). British Journal of Cancer. ISSN 0007-0920. 121(9). doi: 10.1038/s41416-019-0590-7.
• Ommundsen, Nina; Wyller, Torgeir Bruun; Nesbakken, Arild; Bakka, Arne Olav; Jordhøy, Marit Slaaen & Skovlund, Eva [Show all 7 contributors for this article] (2018). Reply to Lawday et al. Colorectal Disease. ISSN 1462-8910. 20(4), p. 350–351. doi: 10.1111/codi.14059.
• Joranger, Pål; Nesbakken, Arild; Hoff, Geir; Sorbye, Halfdan; Oshaug, Arne & Aas, Eline (2015). Modell for å beregne overlevelse og kostnader av behandling for kolorektal cancer. Show summary

  Bakgrunn: Tykktarmskreft (CRC) er en viktig årsak til kreftdødsfall i Norge. Målet med denne studien var (i) å beskrive en kolorektal cancer (CRC) modell for å beregne behandlingskostnader og overlevelse og (ii) validere modellen. Materiale og metode: Vi brukte en semi-Markovmodell med 70 helsetilstander og tok hensyn til alder og tiden som har gått etter viktige inngrep/behandlinger. Modellparametrene var basert på data for 2049 CRC-pasienter ved Oslo universitetssykehus (OUS) (overlevelse), Norsk pasientregister (ressursbruk), publisert litteratur og ekspertvurderinger. Modellen fulgte pasienter diagnostisert for CRC ved en alder av 70 år og til død. Resultater: Modellen ble validert for ”face-”, intern-, ”cross”-, og ekstern validitet. Valideringene viste tilfredsstillende samsvar med andre modeller og empiriske estimater for både kostnader og overlevelse (ingen forutgående kalibrering av modellen). I en ”cross”-validering av ti års total overlevelse avvek modellens estimat med 11,5 dager (0,38 måned) sammenlignet med OUS data. Kostnadsestimatene fra vår modell var 0,3% lavere enn estimater fra en irsk modell (3,0, 1,3, -3,6 og 1,2% lavere i en irsk modell for henholdsvis TNM- stadium I, II, III og IV). I en ekstern validering sammenlignet vi relativ overlevelse estimert av modellen med pasientdata fra Kreftregisteret som inneholder et komplett sett med data for CRC pasienter i Norge. Modellen predikerte 3,9% høyere relativ overlevelse enn Kreftregisterets data viser i løpet av første året, og 0,9, 5,6 og 5,6% lavere relativ overlevelse fem, ti og femten år etter diagnose. I en annen ekstern validering ble modellen sammenliknet med empirisk estimerte ("model-free") totale kostnader basert på Norsk pasientregister. Justert for forskjeller i forutsetninger var modellens anslag 3,1% høyere enn de empirisk estimerte. Konklusjoner: CRC-modellen predikerte på en god måte overlevelse og kostnader for de ulike TNM-stadiene, og vil kunne være valid mht å estimere helsemessige og ressursmessige konsekvenser av CRC-behandling.

• Joranger, Pål; Nesbakken, Arild; Hoff, Geir; Sorbye, Halfdan; Oshaug, Arne & Aas, Eline (2014). Development and validation of a Norwegian model for colorectal cancer.
• Ahmed, Deeqa; Ågesen, Trude Holmeide; Danielsen, Stine Aske; Bretthauer, Michael; Thiis-Evensen, Espen & Hoff, Geir [Show all 10 contributors for this article] (2012). METHYLATION BASED BIOMARKERS FOR NON-INVASIVE EARLY DETECTION OF COLORECTAL CANCER. Annals of Oncology. ISSN 0923-7534. 23, p. 23–23.
• Holmebakk, T.; Solbakken, Arne Mide; Mala, Tom & Nesbakken, Arild (2011). Clinical Prediction of Survival by Surgeons for Patients With Incurable Malignant Disease. European Journal of Cancer. ISSN 0959-8049. 47, p. S221–S221.
• Pretorius, M; Bondi, J; Bukholm, Ida Rashida Khan; Merok, Marianne Aarstad; Nesbakken, Arild & Lothe, Ragnhild A [Show all 7 contributors for this article] (2010). LARGE-SCALE GENOMIC INSTABILITY IN COLON ADENOCARCINOMAS AND CORRELATION WITH PATIENT OUTCOME. Cellular Oncology. ISSN 1570-5870. 32(3), p. 179–179.
• Ågesen, Trude Holmeide; Berg, Marianne; Cekaite, Lina; Thiis-Evensen, Espen; Merok, Marianne Aarstad & Nesbakken, Arild [Show all 8 contributors for this article] (2010). Transcriptional profiling of early onset colorectal cancer identifies CLC as a potential cancer susceptibility gene. European Journal of Cancer. ISSN 0959-8049. 8(5), p. 205–205.

View all works in Cristin